Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
KR20210008380A
Antibody variant combinations and uses thereof
JP2019163262A
Dimeric proteins with triple mutations
EP3743440A1
Polypeptide variants and uses thereof
MX2019014407A
Therapeutic antibodies based on mutated igg hexamers.
JP2018138022A
Human igg1 fc region variants and uses thereof
AU2018218345A1
Polypeptide variants and uses thereof
CA3041988A1
Polypeptide variants and uses thereof
US2020123237A1
Antibodies and methods of use thereof in treatment of infectious disease
WO2017093448A1
Anti-dr5 antibodies and methods of use thereof
EP3632462A1
Dimeric protein with triple mutations
AU2013285355A1
Dimeric protein with triple mutations
SG10202001480WA
Human igg1 fc region variants and uses thereof
KR20160007478A
Human igg1 fc region variants and uses thereof
BR112014000264A2
methods for increasing and decreasing an effector function of a parental polypeptide and a parent antibody, for enhancing an effector function of a combination of at least one first and a second parent polypeptide, for inducing an effector response against a cell, cell membrane, or virion, to increase the specificity of a combination of at least a first and a second parent polypeptide, variant of a parent polypeptide, composition, and part kit
